Girard Partners LTD. increased its position in Eli Lilly and Company (NYSE:LLY) by 18.7% during the first quarter, Holdings Channel reports. The firm owned 7,343 shares of the company’s stock after buying an additional 1,157 shares during the period. Girard Partners LTD.’s holdings in Eli Lilly and Company were worth $618,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. ETRADE Capital Management LLC raised its position in shares of Eli Lilly and Company by 37.7% in the third quarter. ETRADE Capital Management LLC now owns 12,904 shares of the company’s stock worth $1,036,000 after buying an additional 3,531 shares during the period. Arthur M. Cohen & Associates LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $3,485,000. Norway Savings Bank bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $260,000. Hodges Capital Management Inc. raised its position in shares of Eli Lilly and Company by 11.4% in the fourth quarter. Hodges Capital Management Inc. now owns 17,413 shares of the company’s stock worth $1,281,000 after buying an additional 1,784 shares during the period. Finally, Wechter Feldman Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $935,000. 75.44% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE LLY) opened at 81.88 on Friday. The firm has a market capitalization of $86.49 billion, a P/E ratio of 39.59 and a beta of 0.36. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The firm’s 50-day moving average is $80.08 and its 200-day moving average is $78.91.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.02. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. The firm had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.22 billion. During the same period last year, the firm posted $0.83 earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, equities analysts expect that Eli Lilly and Company will post $4.12 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, June 9th. Stockholders of record on Monday, May 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date was Thursday, May 11th. Eli Lilly and Company’s payout ratio is 100.48%.

ILLEGAL ACTIVITY NOTICE: “Girard Partners LTD. Boosts Stake in Eli Lilly and Company (LLY)” was first published by Financial Market News and is the sole property of of Financial Market News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.financial-market-news.com/2017/06/17/girard-partners-ltd-boosts-stake-in-eli-lilly-and-company-lly.html.

A number of equities analysts recently issued reports on LLY shares. Jefferies Group LLC reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, February 17th. Vetr lowered shares of Eli Lilly and Company from a “sell” rating to a “strong sell” rating and set a $70.44 price target on the stock. in a report on Monday, February 20th. Leerink Swann reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, March 20th. Credit Suisse Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Tuesday, March 21st. Finally, Zacks Investment Research raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a report on Tuesday, April 4th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $87.59.

In other news, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and Company stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the sale, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Enrique A. Conterno sold 25,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $82.76, for a total value of $2,069,000.00. Following the sale, the senior vice president now directly owns 114,217 shares in the company, valued at $9,452,598.92. The disclosure for this sale can be found here. Insiders have sold 259,733 shares of company stock worth $21,829,137 over the last three months. Insiders own 0.20% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.